Skip to content
AnalystLens

Leidos Holdings 8-K Report, Financial Results (Aug 4, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed August 4, 2026
Period End
August 4, 2026
Security
LDOS
In the record · 2016–202610-K1210-Q338-K130

LDOS filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 130 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Aug ’18Aug ’18
  2. Leadership change8-K · Oct ’20Oct ’20
  3. Leadership change8-K · Feb ’23Feb ’23
  4. Material agreement8-K · Feb ’25Feb ’25

Summary

Summary of the 8-K filed August 4, 2026. Cited figures are marked; the original filing is the authoritative source.

Leidos Holdings, Inc. reported results for its second fiscal quarter ended July 3, 2026, in a press release furnished as Exhibit 99.1 to this Form 8-K.

Revenues were $4.56 billiona, up 7% year-over-year (4% organically), and net income was $356 million, or $2.81 per diluted share, versus $393 million and $3.01 a year earlier. Net income reflected $29 million of costs tied to the Entrust Solutions Group acquisition, the pending joint venture with Analogic Corporation, and restructuring associated with the NorthStar 2030 re-alignment. Adjusted EBITDA was $631 million with a 13.8% margin (15.2% a year ago), and non-GAAP diluted EPS rose 2% to $3.26.

Cash generation was strong: net cash provided by operating activities was $793 millionb and non-GAAP free cash flow was $761 million for the quarter. Net bookings were $4.9 billion with a book-to-bill ratio of 1.1, bringing total backlog to $48.7 billion, of which $10.2 billion was funded.

The company repaid $300 millionc of commercial paper and returned $127 million to shareholders, and it ended the quarter with $748 million of cash and $6.0 billion of debt. Management raised fiscal 2026 guidance: revenues of $18.20 to $18.40 billion (previously $18.00 to $18.40 billion), non-GAAP diluted EPS of $12.20 to $12.50 (previously $12.10 to $12.50), operating cash flow of approximately $1.85 billion (previously approximately $1.80 billion), and an unchanged adjusted EBITDA margin in the mid-13% range.

Key Highlights

  1. Q2 revenues of $4.56 billion, up 7% year-over-year, including 4% organic growth; Homeland revenues rose 32% to $1.02 billion, including $141 million from the Entrust acquisition.
  2. GAAP net income fell to $356 million ($2.81 per diluted share) from $393 million ($3.01), while non-GAAP diluted EPS increased 2% to $3.26.
  3. Adjusted EBITDA was $631 million with a 13.8% margin, down from $647 million and 15.2% a year earlier; Health revenues declined 8% on lower medical disability exam volumes.
  4. Operating cash flow of $793 million and non-GAAP free cash flow of $761 million in the quarter, with a free cash flow conversion ratio of 185%.
  5. Net bookings of $4.9 billion (book-to-bill 1.1) lifted total backlog to $48.7 billion, of which $10.2 billion was funded.
  6. Fiscal 2026 guidance raised for revenues ($18.20–$18.40 billion), non-GAAP diluted EPS ($12.20–$12.50), and operating cash flow (about $1.85 billion).
  7. Notable awards included a $475 million U.S. Air Force AIS contract, a $456 million GSA Military OneSource contract, and a $350 million U.S. Air Force electronic warfare contract modification.

Frequently Asked Questions

  1. How did Leidos perform in the second quarter of fiscal 2026?

    Revenues were $4.56 billion, up 7% year-over-year and 4% organically. Net income was $356 million, or $2.81 per diluted share, down from $393 million and $3.01 a year earlier, reflecting acquisition, integration and restructuring costs. Non-GAAP diluted EPS rose 2% to $3.26.

  2. Why did profitability decline compared with the prior-year quarter?

    The filing attributes the decline partly to $29 million in costs associated with the Entrust acquisition, the pending Analogic Corporation joint venture, and NorthStar 2030 restructuring. Management also noted that the year-ago quarter benefited from several one-time, non-operational gains, including a $25 million insurance reimbursement for legal costs. Health segment margins fell on lower medical disability exam volumes.

  3. What did Leidos change in its fiscal 2026 guidance?

    Revenue guidance was narrowed upward to $18.20–$18.40 billion from $18.00–$18.40 billion, non-GAAP diluted EPS was raised to $12.20–$12.50 from $12.10–$12.50, and operating cash flow was raised to approximately $1.85 billion from approximately $1.80 billion. The adjusted EBITDA margin guidance of mid-13% was unchanged.

  4. How strong is the company's backlog and bookings?

    Net bookings were $4.9 billion in the quarter, a book-to-bill ratio of 1.1. Total backlog reached $48.7 billion, including $10.2 billion of funded backlog. The filing states that trailing-twelve-month book-to-bill of 1.1 drove year-over-year growth in total and funded backlog of 5% and 44%, respectively.

  5. What was Leidos's cash position and capital allocation during the quarter?

    Operating cash flow was $793 million and non-GAAP free cash flow was $761 million. The company paid down $300 million of debt and returned $127 million to shareholders, including $72 million in share repurchases and $55 million in dividends. At quarter end it held $748 million in cash and cash equivalents and $6.0 billion of debt.